3E0

• 3E00X05 Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach Billable
• 3E00X0M Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach Billable
• 3E00X28 Introduction of Oxazolidinones into Skin and Mucous Membranes, External Approach Billable
• 3E00X29 Introduction of Other Anti-infective into Skin and Mucous Membranes, External Approach Billable
• 3E00X3Z Introduction of Anti-inflammatory into Skin and Mucous Membranes, External Approach Billable
• 3E00X4Z Introduction of Serum, Toxoid and Vaccine into Skin and Mucous Membranes, External Approach Billable
• 3E00XBZ Introduction of Anesthetic Agent into Skin and Mucous Membranes, External Approach Billable
• 3E00XGC Introduction of Other Therapeutic Substance into Skin and Mucous Membranes, External Approach Billable
• 3E00XGF Introduction of Other Enzymatic/Chemical Agent into Skin and Mucous Membranes, External Approach Billable
• 3E00XKZ Introduction of Other Diagnostic Substance into Skin and Mucous Membranes, External Approach Billable
• 3E00XMZ Introduction of Pigment into Skin and Mucous Membranes, External Approach Billable
• 3E00XNZ Introduction of Analgesics, Hypnotics, Sedatives into Skin and Mucous Membranes, External Approach Billable
• 3E00XTZ Introduction of Destructive Agent into Skin and Mucous Membranes, External Approach Billable
• 3E0102A Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Open Approach Billable
• 3E01305 Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E0130M Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E01328 Introduction of Oxazolidinones into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E01329 Introduction of Other Anti-infective into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E0132A Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E0133Z Introduction of Anti-inflammatory into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E01340 Introduction of Influenza Vaccine into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E0134Z Introduction of Serum, Toxoid and Vaccine into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E0136Z Introduction of Nutritional Substance into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E0137Z Introduction of Electrolytic and Water Balance Substance into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E013BZ Introduction of Anesthetic Agent into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E013GC Introduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E013HZ Introduction of Radioactive Substance into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E013KZ Introduction of Other Diagnostic Substance into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E013NZ Introduction of Analgesics, Hypnotics, Sedatives into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E013TZ Introduction of Destructive Agent into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E013VG Introduction of Insulin into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E013VJ Introduction of Other Hormone into Subcutaneous Tissue, Percutaneous Approach Billable
• 3E01XGF Introduction of Other Enzymatic/Chemical Agent into Subcutaneous Tissue, External Approach Billable
• 3E02305 Introduction of Other Antineoplastic into Muscle, Percutaneous Approach Billable
• 3E0230M Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach Billable
• 3E02328 Introduction of Oxazolidinones into Muscle, Percutaneous Approach Billable
• 3E02329 Introduction of Other Anti-infective into Muscle, Percutaneous Approach Billable
• 3E0233Z Introduction of Anti-inflammatory into Muscle, Percutaneous Approach Billable
• 3E02340 Introduction of Influenza Vaccine into Muscle, Percutaneous Approach Billable
• 3E0234Z Introduction of Serum, Toxoid and Vaccine into Muscle, Percutaneous Approach Billable
• 3E0236Z Introduction of Nutritional Substance into Muscle, Percutaneous Approach Billable
• 3E0237Z Introduction of Electrolytic and Water Balance Substance into Muscle, Percutaneous Approach Billable
• 3E023BZ Introduction of Anesthetic Agent into Muscle, Percutaneous Approach Billable
• 3E023GC Introduction of Other Therapeutic Substance into Muscle, Percutaneous Approach Billable
• 3E023HZ Introduction of Radioactive Substance into Muscle, Percutaneous Approach Billable
• 3E023KZ Introduction of Other Diagnostic Substance into Muscle, Percutaneous Approach Billable
• 3E023NZ Introduction of Analgesics, Hypnotics, Sedatives into Muscle, Percutaneous Approach Billable
• 3E023TZ Introduction of Destructive Agent into Muscle, Percutaneous Approach Billable
• 3E03002 Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach Billable
• 3E03003 Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach Billable
• 3E03005 Introduction of Other Antineoplastic into Peripheral Vein, Open Approach Billable
• 3E0300M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach Billable
• 3E0300P Introduction of Clofarabine into Peripheral Vein, Open Approach Billable
• 3E03016 Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Open Billable
• 3E03017 Introduction of Other Thrombolytic into Peripheral Vein, Open Approach Billable
• 3E03028 Introduction of Oxazolidinones into Peripheral Vein, Open Approach Billable
• 3E03029 Introduction of Other Anti-infective into Peripheral Vein, Open Approach Billable
• 3E0303Z Introduction of Anti-inflammatory into Peripheral Vein, Open Approach Billable
• 3E0304Z Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Open Approach Billable
• 3E0306Z Introduction of Nutritional Substance into Peripheral Vein, Open Approach Billable
• 3E0307Z Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Open Approach Billable
• 3E030FZ Introduction of Intracirculatory Anesthetic into Peripheral Vein, Open Approach Billable
• 3E030GC Introduction of Other Therapeutic Substance into Peripheral Vein, Open Approach Billable
• 3E030GN Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach Billable
• 3E030HZ Introduction of Radioactive Substance into Peripheral Vein, Open Approach Billable
• 3E030KZ Introduction of Other Diagnostic Substance into Peripheral Vein, Open Approach Billable
• 3E030NZ Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Open Approach Billable
• 3E030PZ Introduction of Platelet Inhibitor into Peripheral Vein, Open Approach Billable
• 3E030RZ Introduction of Antiarrhythmic into Peripheral Vein, Open Approach Billable
• 3E030TZ Introduction of Destructive Agent into Peripheral Vein, Open Approach Billable
• 3E030U0 Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Open Approach Billable
• 3E030U1 Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach Billable
• 3E030VG Introduction of Insulin into Peripheral Vein, Open Approach Billable
• 3E030VH Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Open Approach Billable
• 3E030VJ Introduction of Other Hormone into Peripheral Vein, Open Approach Billable
• 3E030WK Introduction of Immunostimulator into Peripheral Vein, Open Billable
• 3E030WL Introduction of Immunosuppressive into Peripheral Vein, Open Billable
• 3E030XZ Introduction of Vasopressor into Peripheral Vein, Open Approach Billable
• 3E03302 Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach Billable
• 3E03303 Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach Billable
• 3E03305 Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach Billable
• 3E0330M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach Billable
• 3E0330P Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach Billable
• 3E03316 Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Percutaneous Billable
• 3E03317 Introduction of Other Thrombolytic into Peripheral Vein, Percutaneous Approach Billable
• 3E03328 Introduction of Oxazolidinones into Peripheral Vein, Percutaneous Approach Billable
• 3E03329 Introduction of Other Anti-infective into Peripheral Vein, Percutaneous Approach Billable
• 3E0333Z Introduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach Billable
• 3E0334Z Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Percutaneous Approach Billable
• 3E0336Z Introduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach Billable
• 3E0337Z Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Percutaneous Approach Billable
• 3E033AZ Introduction of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach Billable
• 3E033FZ Introduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach Billable
• 3E033GC Introduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach Billable
• 3E033GN Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Percutaneous Approach Billable
• 3E033GQ Introduction of Glucarpidase into Peripheral Vein, Percutaneous Approach Billable
• 3E033GR Introduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein, Percutaneous Approach Billable
• 3E033HZ Introduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach Billable
• 3E033KZ Introduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach Billable
• 3E033NZ Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach Billable
• 3E033PZ Introduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach Billable
• 3E033RZ Introduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach Billable
• 3E033TZ Introduction of Destructive Agent into Peripheral Vein, Percutaneous Approach Billable
• 3E033U0 Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach Billable
• 3E033U1 Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach Billable
• 3E033VG Introduction of Insulin into Peripheral Vein, Percutaneous Approach Billable
• 3E033VH Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Percutaneous Approach Billable
• 3E033VJ Introduction of Other Hormone into Peripheral Vein, Percutaneous Approach Billable
• 3E033WK Introduction of Immunostimulator into Peripheral Vein, Percutaneous Billable
• 3E033WL Introduction of Immunosuppressive into Peripheral Vein, Percutaneous Billable
• 3E033XZ Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach Billable
• 3E04002 Introduction of High-dose Interleukin-2 into Central Vein, Open Approach Billable
• 3E04003 Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach Billable
• 3E04005 Introduction of Other Antineoplastic into Central Vein, Open Approach Billable
• 3E0400M Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach Billable
• 3E0400P Introduction of Clofarabine into Central Vein, Open Approach Billable
• 3E04016 Introduction of Recombinant Human-activated Protein C into Central Vein, Open Billable
• 3E04017 Introduction of Other Thrombolytic into Central Vein, Open Approach Billable
• 3E04028 Introduction of Oxazolidinones into Central Vein, Open Approach Billable
• 3E04029 Introduction of Other Anti-infective into Central Vein, Open Approach Billable
• 3E0403Z Introduction of Anti-inflammatory into Central Vein, Open Approach Billable
• 3E0404Z Introduction of Serum, Toxoid and Vaccine into Central Vein, Open Approach Billable
• 3E0406Z Introduction of Nutritional Substance into Central Vein, Open Approach Billable
• 3E0407Z Introduction of Electrolytic and Water Balance Substance into Central Vein, Open Approach Billable
• 3E040FZ Introduction of Intracirculatory Anesthetic into Central Vein, Open Approach Billable
• 3E040GC Introduction of Other Therapeutic Substance into Central Vein, Open Approach Billable
• 3E040GN Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach Billable
• 3E040HZ Introduction of Radioactive Substance into Central Vein, Open Approach Billable
• 3E040KZ Introduction of Other Diagnostic Substance into Central Vein, Open Approach Billable
• 3E040NZ Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Open Approach Billable
• 3E040PZ Introduction of Platelet Inhibitor into Central Vein, Open Approach Billable
• 3E040RZ Introduction of Antiarrhythmic into Central Vein, Open Approach Billable
• 3E040TZ Introduction of Destructive Agent into Central Vein, Open Approach Billable
• 3E040VG Introduction of Insulin into Central Vein, Open Approach Billable
• 3E040VH Introduction of Human B-type Natriuretic Peptide into Central Vein, Open Approach Billable
• 3E040VJ Introduction of Other Hormone into Central Vein, Open Approach Billable
• 3E040WK Introduction of Immunostimulator into Central Vein, Open Billable
• 3E040WL Introduction of Immunosuppressive into Central Vein, Open Billable
• 3E040XZ Introduction of Vasopressor into Central Vein, Open Approach Billable
• 3E04302 Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach Billable
• 3E04303 Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach Billable
• 3E04305 Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach Billable
• 3E0430M Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach Billable
• 3E0430P Introduction of Clofarabine into Central Vein, Percutaneous Approach Billable
• 3E04316 Introduction of Recombinant Human-activated Protein C into Central Vein, Percutaneous Billable
• 3E04317 Introduction of Other Thrombolytic into Central Vein, Percutaneous Approach Billable
• 3E04328 Introduction of Oxazolidinones into Central Vein, Percutaneous Approach Billable
• 3E04329 Introduction of Other Anti-infective into Central Vein, Percutaneous Approach Billable
• 3E0433Z Introduction of Anti-inflammatory into Central Vein, Percutaneous Approach Billable
• 3E0434Z Introduction of Serum, Toxoid and Vaccine into Central Vein, Percutaneous Approach Billable
• 3E0436Z Introduction of Nutritional Substance into Central Vein, Percutaneous Approach Billable
• 3E0437Z Introduction of Electrolytic and Water Balance Substance into Central Vein, Percutaneous Approach Billable
• 3E043AZ Introduction of Embryonic Stem Cells into Central Vein, Percutaneous Approach Billable
• 3E043FZ Introduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach Billable
• 3E043GC Introduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach Billable
• 3E043GN Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Percutaneous Approach Billable
• 3E043GQ Introduction of Glucarpidase into Central Vein, Percutaneous Approach Billable
• 3E043GR Introduction of Other Therapeutic Monoclonal Antibody into Central Vein, Percutaneous Approach Billable
• 3E043HZ Introduction of Radioactive Substance into Central Vein, Percutaneous Approach Billable
• 3E043KZ Introduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach Billable
• 3E043NZ Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach Billable
• 3E043PZ Introduction of Platelet Inhibitor into Central Vein, Percutaneous Approach Billable
• 3E043RZ Introduction of Antiarrhythmic into Central Vein, Percutaneous Approach Billable
• 3E043TZ Introduction of Destructive Agent into Central Vein, Percutaneous Approach Billable
• 3E043VG Introduction of Insulin into Central Vein, Percutaneous Approach Billable
• 3E043VH Introduction of Human B-type Natriuretic Peptide into Central Vein, Percutaneous Approach Billable
• 3E043VJ Introduction of Other Hormone into Central Vein, Percutaneous Approach Billable
• 3E043WK Introduction of Immunostimulator into Central Vein, Percutaneous Billable
• 3E043WL Introduction of Immunosuppressive into Central Vein, Percutaneous Billable
• 3E043XZ Introduction of Vasopressor into Central Vein, Percutaneous Approach Billable
• 3E05002 Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach Billable
• 3E05003 Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach Billable
• 3E05005 Introduction of Other Antineoplastic into Peripheral Artery, Open Approach Billable
• 3E0500M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach Billable
• 3E0500P Introduction of Clofarabine into Peripheral Artery, Open Approach Billable
• 3E05016 Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Open Billable
• 3E05017 Introduction of Other Thrombolytic into Peripheral Artery, Open Approach Billable
• 3E05028 Introduction of Oxazolidinones into Peripheral Artery, Open Approach Billable
• 3E05029 Introduction of Other Anti-infective into Peripheral Artery, Open Approach Billable
• 3E0503Z Introduction of Anti-inflammatory into Peripheral Artery, Open Approach Billable
• 3E0504Z Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Open Approach Billable
• 3E0506Z Introduction of Nutritional Substance into Peripheral Artery, Open Approach Billable
• 3E0507Z Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Open Approach Billable
• 3E050FZ Introduction of Intracirculatory Anesthetic into Peripheral Artery, Open Approach Billable
• 3E050GC Introduction of Other Therapeutic Substance into Peripheral Artery, Open Approach Billable
• 3E050GN Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach Billable
• 3E050HZ Introduction of Radioactive Substance into Peripheral Artery, Open Approach Billable
• 3E050KZ Introduction of Other Diagnostic Substance into Peripheral Artery, Open Approach Billable
• 3E050NZ Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Open Approach Billable
• 3E050PZ Introduction of Platelet Inhibitor into Peripheral Artery, Open Approach Billable
• 3E050RZ Introduction of Antiarrhythmic into Peripheral Artery, Open Approach Billable
• 3E050TZ Introduction of Destructive Agent into Peripheral Artery, Open Approach Billable
• 3E050VG Introduction of Insulin into Peripheral Artery, Open Approach Billable
• 3E050VH Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Open Approach Billable
• 3E050VJ Introduction of Other Hormone into Peripheral Artery, Open Approach Billable
• 3E050WK Introduction of Immunostimulator into Peripheral Artery, Open Billable
• 3E050WL Introduction of Immunosuppressive into Peripheral Artery, Open Billable
• 3E050XZ Introduction of Vasopressor into Peripheral Artery, Open Approach Billable
• 3E05302 Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach Billable
• 3E05303 Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach Billable
• 3E05305 Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach Billable
• 3E0530M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach Billable
• 3E0530P Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach Billable
• 3E05316 Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Percutaneous Billable
• 3E05317 Introduction of Other Thrombolytic into Peripheral Artery, Percutaneous Approach Billable
• 3E05328 Introduction of Oxazolidinones into Peripheral Artery, Percutaneous Approach Billable
• 3E05329 Introduction of Other Anti-infective into Peripheral Artery, Percutaneous Approach Billable
• 3E0533Z Introduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach Billable
• 3E0534Z Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Percutaneous Approach Billable
• 3E0536Z Introduction of Nutritional Substance into Peripheral Artery, Percutaneous Approach Billable
• 3E0537Z Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Percutaneous Approach Billable
• 3E053FZ Introduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach Billable
• 3E053GC Introduction of Other Therapeutic Substance into Peripheral Artery, Percutaneous Approach Billable
• 3E053GN Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Percutaneous Approach Billable
• 3E053HZ Introduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach Billable
• 3E053KZ Introduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach Billable
• 3E053NZ Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Percutaneous Approach Billable
• 3E053PZ Introduction of Platelet Inhibitor into Peripheral Artery, Percutaneous Approach Billable
• 3E053RZ Introduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach Billable
• 3E053TZ Introduction of Destructive Agent into Peripheral Artery, Percutaneous Approach Billable
• 3E053VG Introduction of Insulin into Peripheral Artery, Percutaneous Approach Billable
• 3E053VH Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Percutaneous Approach Billable
• 3E053VJ Introduction of Other Hormone into Peripheral Artery, Percutaneous Approach Billable
• 3E053WK Introduction of Immunostimulator into Peripheral Artery, Percutaneous Billable
• 3E053WL Introduction of Immunosuppressive into Peripheral Artery, Percutaneous Billable
• 3E053XZ Introduction of Vasopressor into Peripheral Artery, Percutaneous Approach Billable
• 3E06002 Introduction of High-dose Interleukin-2 into Central Artery, Open Approach Billable
• 3E06003 Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach Billable
• 3E06005 Introduction of Other Antineoplastic into Central Artery, Open Approach Billable
• 3E0600M Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach Billable
• 3E0600P Introduction of Clofarabine into Central Artery, Open Approach Billable
• 3E06016 Introduction of Recombinant Human-activated Protein C into Central Artery, Open Billable
• 3E06017 Introduction of Other Thrombolytic into Central Artery, Open Approach Billable
• 3E06028 Introduction of Oxazolidinones into Central Artery, Open Approach Billable
• 3E06029 Introduction of Other Anti-infective into Central Artery, Open Approach Billable
• 3E0603Z Introduction of Anti-inflammatory into Central Artery, Open Approach Billable
• 3E0604Z Introduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach Billable
• 3E0606Z Introduction of Nutritional Substance into Central Artery, Open Approach Billable
• 3E0607Z Introduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach Billable
• 3E060FZ Introduction of Intracirculatory Anesthetic into Central Artery, Open Approach Billable
• 3E060GC Introduction of Other Therapeutic Substance into Central Artery, Open Approach Billable
• 3E060GN Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach Billable
• 3E060HZ Introduction of Radioactive Substance into Central Artery, Open Approach Billable
• 3E060KZ Introduction of Other Diagnostic Substance into Central Artery, Open Approach Billable
• 3E060NZ Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach Billable
• 3E060PZ Introduction of Platelet Inhibitor into Central Artery, Open Approach Billable
• 3E060RZ Introduction of Antiarrhythmic into Central Artery, Open Approach Billable
• 3E060TZ Introduction of Destructive Agent into Central Artery, Open Approach Billable
• 3E060VG Introduction of Insulin into Central Artery, Open Approach Billable
• 3E060VH Introduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach Billable
• 3E060VJ Introduction of Other Hormone into Central Artery, Open Approach Billable
• 3E060WK Introduction of Immunostimulator into Central Artery, Open Billable
• 3E060WL Introduction of Immunosuppressive into Central Artery, Open Billable
• 3E060XZ Introduction of Vasopressor into Central Artery, Open Approach Billable
• 3E06302 Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach Billable
• 3E06303 Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach Billable
• 3E06305 Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach Billable
• 3E0630M Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach Billable
• 3E0630P Introduction of Clofarabine into Central Artery, Percutaneous Approach Billable
• 3E06316 Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous Billable
• 3E06317 Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach Billable
• 3E06328 Introduction of Oxazolidinones into Central Artery, Percutaneous Approach Billable
• 3E06329 Introduction of Other Anti-infective into Central Artery, Percutaneous Approach Billable
• 3E0633Z Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach Billable
• 3E0634Z Introduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach Billable
• 3E0636Z Introduction of Nutritional Substance into Central Artery, Percutaneous Approach Billable
• 3E0637Z Introduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach Billable
• 3E063FZ Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach Billable
• 3E063GC Introduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach Billable
• 3E063GN Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach Billable
• 3E063HZ Introduction of Radioactive Substance into Central Artery, Percutaneous Approach Billable
• 3E063KZ Introduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach Billable
• 3E063NZ Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach Billable
• 3E063PZ Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach Billable
• 3E063RZ Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach Billable
• 3E063TZ Introduction of Destructive Agent into Central Artery, Percutaneous Approach Billable
• 3E063VG Introduction of Insulin into Central Artery, Percutaneous Approach Billable
• 3E063VH Introduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach Billable
• 3E063VJ Introduction of Other Hormone into Central Artery, Percutaneous Approach Billable
• 3E063WK Introduction of Immunostimulator into Central Artery, Percutaneous Billable
• 3E063WL Introduction of Immunosuppressive into Central Artery, Percutaneous Billable
• 3E063XZ Introduction of Vasopressor into Central Artery, Percutaneous Approach Billable
• 3E07016 Introduction of Recombinant Human-activated Protein C into Coronary Artery, Open Billable
• 3E07017 Introduction of Other Thrombolytic into Coronary Artery, Open Approach Billable
• 3E070GC Introduction of Other Therapeutic Substance into Coronary Artery, Open Approach Billable
• 3E070KZ Introduction of Other Diagnostic Substance into Coronary Artery, Open Approach Billable
• 3E070PZ Introduction of Platelet Inhibitor into Coronary Artery, Open Approach Billable
• 3E07316 Introduction of Recombinant Human-activated Protein C into Coronary Artery, Percutaneous Billable
• 3E07317 Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach Billable
• 3E073GC Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Approach Billable
• 3E073KZ Introduction of Other Diagnostic Substance into Coronary Artery, Percutaneous Approach Billable
• 3E073PZ Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach Billable
• 3E074GC Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Endoscopic Approach Billable
• 3E08016 Introduction of Recombinant Human-activated Protein C into Heart, Open Billable
• 3E08017 Introduction of Other Thrombolytic into Heart, Open Approach Billable
• 3E080GC Introduction of Other Therapeutic Substance into Heart, Open Approach Billable
• 3E080KZ Introduction of Other Diagnostic Substance into Heart, Open Approach Billable
• 3E080PZ Introduction of Platelet Inhibitor into Heart, Open Approach Billable
• 3E08316 Introduction of Recombinant Human-activated Protein C into Heart, Percutaneous Billable
• 3E08317 Introduction of Other Thrombolytic into Heart, Percutaneous Approach Billable
• 3E083GC Introduction of Other Therapeutic Substance into Heart, Percutaneous Approach Billable
• 3E083KZ Introduction of Other Diagnostic Substance into Heart, Percutaneous Approach Billable
• 3E083PZ Introduction of Platelet Inhibitor into Heart, Percutaneous Approach Billable
• 3E084GC Introduction of Other Therapeutic Substance into Heart, Percutaneous Endoscopic Approach Billable
• 3E09305 Introduction of Other Antineoplastic into Nose, Percutaneous Approach Billable
• 3E0930M Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach Billable
• 3E09328 Introduction of Oxazolidinones into Nose, Percutaneous Approach Billable
• 3E09329 Introduction of Other Anti-infective into Nose, Percutaneous Approach Billable
• 3E0933Z Introduction of Anti-inflammatory into Nose, Percutaneous Approach Billable
• 3E0934Z Introduction of Serum, Toxoid and Vaccine into Nose, Percutaneous Approach Billable
• 3E093BZ Introduction of Anesthetic Agent into Nose, Percutaneous Approach Billable
• 3E093GC Introduction of Other Therapeutic Substance into Nose, Percutaneous Approach Billable
• 3E093HZ Introduction of Radioactive Substance into Nose, Percutaneous Approach Billable
• 3E093KZ Introduction of Other Diagnostic Substance into Nose, Percutaneous Approach Billable
• 3E093NZ Introduction of Analgesics, Hypnotics, Sedatives into Nose, Percutaneous Approach Billable
• 3E093TZ Introduction of Destructive Agent into Nose, Percutaneous Approach Billable
• 3E09705 Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening Billable
• 3E0970M Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening Billable
• 3E09728 Introduction of Oxazolidinones into Nose, Via Natural or Artificial Opening Billable
• 3E09729 Introduction of Other Anti-infective into Nose, Via Natural or Artificial Opening Billable
• 3E0973Z Introduction of Anti-inflammatory into Nose, Via Natural or Artificial Opening Billable
• 3E0974Z Introduction of Serum, Toxoid and Vaccine into Nose, Via Natural or Artificial Opening Billable
• 3E097BZ Introduction of Anesthetic Agent into Nose, Via Natural or Artificial Opening Billable
• 3E097GC Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening Billable
• 3E097HZ Introduction of Radioactive Substance into Nose, Via Natural or Artificial Opening Billable
• 3E097KZ Introduction of Other Diagnostic Substance into Nose, Via Natural or Artificial Opening Billable
• 3E097NZ Introduction of Analgesics, Hypnotics, Sedatives into Nose, Via Natural or Artificial Opening Billable
• 3E097TZ Introduction of Destructive Agent into Nose, Via Natural or Artificial Opening Billable
• 3E09X05 Introduction of Other Antineoplastic into Nose, External Approach Billable
• 3E09X0M Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach Billable
• 3E09X28 Introduction of Oxazolidinones into Nose, External Approach Billable
• 3E09X29 Introduction of Other Anti-infective into Nose, External Approach Billable
• 3E09X3Z Introduction of Anti-inflammatory into Nose, External Approach Billable
• 3E09X4Z Introduction of Serum, Toxoid and Vaccine into Nose, External Approach Billable
• 3E09XBZ Introduction of Anesthetic Agent into Nose, External Approach Billable
• 3E09XGC Introduction of Other Therapeutic Substance into Nose, External Approach Billable
• 3E09XHZ Introduction of Radioactive Substance into Nose, External Approach Billable
• 3E09XKZ Introduction of Other Diagnostic Substance into Nose, External Approach Billable
• 3E09XNZ Introduction of Analgesics, Hypnotics, Sedatives into Nose, External Approach Billable
• 3E09XTZ Introduction of Destructive Agent into Nose, External Approach Billable
• 3E0A305 Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach Billable
• 3E0A30M Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach Billable
• 3E0A3GC Introduction of Other Therapeutic Substance into Bone Marrow, Percutaneous Approach Billable
• 3E0B304 Introduction of Liquid Brachytherapy Radioisotope into Ear, Percutaneous Approach Billable
• 3E0B305 Introduction of Other Antineoplastic into Ear, Percutaneous Approach Billable
• 3E0B30M Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach Billable
• 3E0B328 Introduction of Oxazolidinones into Ear, Percutaneous Approach Billable
• 3E0B329 Introduction of Other Anti-infective into Ear, Percutaneous Approach Billable
• 3E0B33Z Introduction of Anti-inflammatory into Ear, Percutaneous Approach Billable
• 3E0B3BZ Introduction of Anesthetic Agent into Ear, Percutaneous Approach Billable
• 3E0B3GC Introduction of Other Therapeutic Substance into Ear, Percutaneous Approach Billable
• 3E0B3HZ Introduction of Radioactive Substance into Ear, Percutaneous Approach Billable
• 3E0B3KZ Introduction of Other Diagnostic Substance into Ear, Percutaneous Approach Billable
• 3E0B3NZ Introduction of Analgesics, Hypnotics, Sedatives into Ear, Percutaneous Approach Billable
• 3E0B3TZ Introduction of Destructive Agent into Ear, Percutaneous Approach Billable
• 3E0B704 Introduction of Liquid Brachytherapy Radioisotope into Ear, Via Natural or Artificial Opening Billable
• 3E0B705 Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening Billable
• 3E0B70M Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening Billable
• 3E0B728 Introduction of Oxazolidinones into Ear, Via Natural or Artificial Opening Billable
• 3E0B729 Introduction of Other Anti-infective into Ear, Via Natural or Artificial Opening Billable
• 3E0B73Z Introduction of Anti-inflammatory into Ear, Via Natural or Artificial Opening Billable
• 3E0B7BZ Introduction of Anesthetic Agent into Ear, Via Natural or Artificial Opening Billable
• 3E0B7GC Introduction of Other Therapeutic Substance into Ear, Via Natural or Artificial Opening Billable
• 3E0B7HZ Introduction of Radioactive Substance into Ear, Via Natural or Artificial Opening Billable
• 3E0B7KZ Introduction of Other Diagnostic Substance into Ear, Via Natural or Artificial Opening Billable
• 3E0B7NZ Introduction of Analgesics, Hypnotics, Sedatives into Ear, Via Natural or Artificial Opening Billable
• 3E0B7TZ Introduction of Destructive Agent into Ear, Via Natural or Artificial Opening Billable
• 3E0BX04 Introduction of Liquid Brachytherapy Radioisotope into Ear, External Approach Billable
• 3E0BX05 Introduction of Other Antineoplastic into Ear, External Approach Billable
• 3E0BX0M Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach Billable
• 3E0BX28 Introduction of Oxazolidinones into Ear, External Approach Billable
• 3E0BX29 Introduction of Other Anti-infective into Ear, External Approach Billable
• 3E0BX3Z Introduction of Anti-inflammatory into Ear, External Approach Billable
• 3E0BXBZ Introduction of Anesthetic Agent into Ear, External Approach Billable
• 3E0BXGC Introduction of Other Therapeutic Substance into Ear, External Approach Billable
• 3E0BXHZ Introduction of Radioactive Substance into Ear, External Approach Billable
• 3E0BXKZ Introduction of Other Diagnostic Substance into Ear, External Approach Billable
• 3E0BXNZ Introduction of Analgesics, Hypnotics, Sedatives into Ear, External Approach Billable
• 3E0BXTZ Introduction of Destructive Agent into Ear, External Approach Billable
• 3E0C304 Introduction of Liquid Brachytherapy Radioisotope into Eye, Percutaneous Approach Billable
• 3E0C305 Introduction of Other Antineoplastic into Eye, Percutaneous Approach Billable
• 3E0C30M Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach Billable
• 3E0C328 Introduction of Oxazolidinones into Eye, Percutaneous Approach Billable
• 3E0C329 Introduction of Other Anti-infective into Eye, Percutaneous Approach Billable
• 3E0C33Z Introduction of Anti-inflammatory into Eye, Percutaneous Approach Billable
• 3E0C3BZ Introduction of Anesthetic Agent into Eye, Percutaneous Approach Billable
• 3E0C3GC Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach Billable
• 3E0C3HZ Introduction of Radioactive Substance into Eye, Percutaneous Approach Billable
• 3E0C3KZ Introduction of Other Diagnostic Substance into Eye, Percutaneous Approach Billable
• 3E0C3MZ Introduction of Pigment into Eye, Percutaneous Approach Billable
• 3E0C3NZ Introduction of Analgesics, Hypnotics, Sedatives into Eye, Percutaneous Approach Billable
• 3E0C3SF Introduction of Other Gas into Eye, Percutaneous Approach Billable
• 3E0C3TZ Introduction of Destructive Agent into Eye, Percutaneous Approach Billable
• 3E0C704 Introduction of Liquid Brachytherapy Radioisotope into Eye, Via Natural or Artificial Opening Billable
• 3E0C705 Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening Billable
• 3E0C70M Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening Billable
• 3E0C728 Introduction of Oxazolidinones into Eye, Via Natural or Artificial Opening Billable
• 3E0C729 Introduction of Other Anti-infective into Eye, Via Natural or Artificial Opening Billable
• 3E0C73Z Introduction of Anti-inflammatory into Eye, Via Natural or Artificial Opening Billable
• 3E0C7BZ Introduction of Anesthetic Agent into Eye, Via Natural or Artificial Opening Billable

Version History

How 3E0 appears in each release imported from the official files, newest first.

1. FY 2027 Effective October 1, 2026

   Current

   Administration, Physiological Systems and Anatomical Regions, Introduction

2. FY 2026 Effective October 1, 2025

   Unchanged

   Administration, Physiological Systems and Anatomical Regions, Introduction